Health‐related quality of life among transthyretin amyloid cardiomyopathy patients
暂无分享,去创建一个
S. Poulsen | F. Gustafsson | E. Gude | T. Pilgaard | J. Lehtonen | M. Vakevainen | P. Eldhagen | Dorte Wedell-Wedellsborg | Anne Bagger‐Bahnsen | Merja Vakevainen
[1] J. Smith,et al. Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries , 2022, ESC heart failure.
[2] K. Bay,et al. Suspicion, screening, and diagnosis of wild‐type transthyretin amyloid cardiomyopathy: a systematic literature review , 2022, ESC heart failure.
[3] V. Planté-Bordeneuve,et al. Amyloidosis from the patient perspective: the French daily impact of amyloidosis study , 2022, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[4] J. Fine,et al. Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial , 2021, Journal of medical economics.
[5] T. B. Rasmussen,et al. Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy. , 2021, Journal of the American College of Cardiology.
[6] A. Garay,et al. Quality of life and disease experience in patients with heart failure with reduced ejection fraction in Spain: a mixed-methods study , 2021, BMJ Open.
[7] C. Gudex,et al. Danish population health measured by the EQ-5D-5L , 2021, Scandinavian journal of public health.
[8] M. Maurer,et al. Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: A plain language summary. , 2021, Future cardiology.
[9] U. Gerdtham,et al. Inequality and heterogeneity in health-related quality of life: findings based on a large sample of cross-sectional EQ-5D-5L data from the Swedish general population , 2021, Quality of Life Research.
[10] J. Smith,et al. Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden , 2021, Open Heart.
[11] S. Hohnloser,et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study , 2021, European heart journal. Quality of care & clinical outcomes.
[12] R. Kornowski,et al. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy , 2021, European journal of heart failure.
[13] A. Masri,et al. Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review , 2021, Cardiology and Therapy.
[14] A. Garratt,et al. Norwegian population norms for the EQ-5D-5L: results from a general population survey , 2021, Quality of Life Research.
[15] E. Schulze-Bahr,et al. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK) , 2021, Clinical Research in Cardiology.
[16] M. Maurer,et al. Impact of Tafamidis on Health-Related Quality of Life in Patients with Transthyretin Amyloid Cardiomyopathy (From the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). , 2020, The American journal of cardiology.
[17] B. Popescu,et al. Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City Cardiomyopathy Questionnaire , 2020, Health and Quality of Life Outcomes.
[18] C. O'connor,et al. Depression and heart failure: the lonely comorbidity , 2020, European journal of heart failure.
[19] S. Ajroud‐Driss,et al. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis , 2020, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[20] R. Falk,et al. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR) , 2020, Cardiovascular Drugs and Therapy.
[21] M. Maurer,et al. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable. , 2020, Annual review of medicine.
[22] H. Vase,et al. Diagnostic delay in wild type transthyretin cardiac amyloidosis - A clinical challenge. , 2020, International journal of cardiology.
[23] S. Solomon,et al. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. , 2019, JACC. Heart failure.
[24] M. Maurer,et al. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.
[25] C. Rapezzi,et al. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS) , 2019, European heart journal.
[26] A. Petrie,et al. A new staging system for cardiac transthyretin amyloidosis , 2018, European heart journal.
[27] W. Lenderking,et al. Characterizing the High Disease Burden of Transthyretin Amyloidosis for Patients and Caregivers , 2018, Neurology and Therapy.
[28] M. Halushka,et al. Seven factors predict a delayed diagnosis of cardiac amyloidosis , 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[29] P. Bech,et al. The criterion validity of the web-based Major Depression Inventory when used on clinical suspicion of depression in primary care , 2017, Clinical epidemiology.
[30] K. Juel,et al. DenHeart: Differences in physical and mental health across cardiac diagnoses at hospital discharge. , 2017, Journal of psychosomatic research.
[31] S. Cay,et al. Heart Failure Functional Class Associated with Depression Severity But Not Anxiety Severity. , 2016, Acta Cardiologica Sinica.
[32] E. González-López,et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.
[33] M. Maurer,et al. THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis , 2013, Current medical research and opinion.
[34] F. Salvi,et al. Transthyretin-related amyloidoses and the heart: a clinical overview , 2010, Nature Reviews Cardiology.
[35] C. O'connor,et al. Relation of depression to severity of illness in heart failure (from Heart Failure And a Controlled Trial Investigating Outcomes of Exercise Training [HF-ACTION]). , 2009, The American journal of cardiology.
[36] P. Bech,et al. Applicability and validity of the Major Depression Inventory in patients with Parkinson's disease , 1998 .
[37] A. Kasuya. EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.